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Abstract. Medicines are digitalized as aspects of their regulation and use are embodied in 
or draw from interlinked computerized systems and databases. This paper considers how 
this development changes the delivery of health care, the pharma industry, and regulatory 
and professional structures, as it reconfigures the material character of drugs themselves. It 
draws on the concept of assemblage in presenting a theory-based analysis that explores digi-
tal drugs’ ontological status including how they embody benefit and value. The paper ad-
dresses three interconnected domains – that of use of drugs (practice), of research (episte-
mology) and of regulation (structures).  
Keywords: Pharmaceutical Preparations; Individualized Medicine; Digital Drugs; 
Healthcare; Assemblage  
1 Introduction 
Anatomy: 1. The art of studying the different parts of any organized body, to discover their situa-
tion, structure, and economy; dissection. […] 4. The act of dividing anything, corporeal or intellec-
tual, for the purpose of examining its parts; analysis; as, the anatomy of a discourse. 
http://en.wiktionary.org/wiki/anatomy 
 
Medicines1 and the ways we use and regulate them are changing, transformed by 
digitalization [1]. This reconfiguration is associated with visions of scientific, ther-
                                                 
1 In this paper we use the word medicines and drugs almost as synonyms. We recognise however 
that they offer slight but significant shifts of emphasis. ‘Medicine’  evokes the practice of med i-
cine and hence the practices of medicines, while drug evokes the manufactured product and its 
chemical character/materiality. Thus in this  most basic sense the thing we address has an inhe r-
ent multiplicity. The US National Library of Medicine thesaurus (MeSH – Medical Subject  
Heading) avoids this tension in its  own way using the term Pharmaceutical Preparations – “Drugs 
intended for human or veterinary use, presented in  their finished dosage form ” (NLM  - Medical 
Subject Headings – 2014 -  Unique ID D004364 - 
http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?mode=&term=Pharmaceutical+Preparation
s&field=entry – Accessed 15 Sept 2014).  
apeutic, managerial and financial breakthroughs from ‘better’ medicines and in 
particular ‘better’ digitally mediated medicine use practices. Expectations include: 
help in meeting the needs of aging populations with multiple chronic diseases, the 
targeting of medicines to individuals (personalization) to significantly increase effi-
cacy and reduce overall cost, and computerized clinical decision support that can 
reduce the burden of harm caused by adverse drug events (ADEs). The pharma 
industry too is reconfiguring as it faces increasing competition from ‘generics’, 
reductions in the pipeline of new medicines entering the market and the ‘patent 
cliff’ off which large pharma companies fear to fall [2, 3]. Such pressures spur 
changes in how current drugs are marketed, distributed and paid for [4]. Pharma-
ceutical business models are realigned to build new relations between patients, 
health care institutions and the pharma industry, with drug products enmeshed in 
or recast as a set of services, and with payment (pricing/reimbursement) shifting 
from the ‘product’ to outcomes.  
 The digitalization of medicines is reflected in a number of overlapping areas of 
contemporary research and development including electronic prescribing, stratified medi-
cine, personalized medicine, smart drug platforms, medical profiling, pharmacovigilance, value 
based pricing and pharmacogenomics (Table 1). The specifics of the ‘breakthrough’ vi-
sion vary, as do the digital mechanisms and resources that are imagined or de-
ployed, but taken overall these initiatives seem to offer new possibilities for thera-
peutic improvement and innovation through digitally mediated ways of using 
drugs. We believe they also foreshadow multiple possible changes in broader med-
ical practices, institutional structures, value chains and business models.  
This paper presents a theory-based view of what we term digital drugs, including 
how they embody benefit or value. The work is part of the scoping of a RCUK 
funded project addressing how, why and with what consequence medicines are 
digitalized. In contrast to the established view of medicines as artefacts located in a 
stage-based model of linear progression from drug development, through innova-
tion and testing to approval and clinical use [5] this work sees drugs as constituted 
‘in-use’[6], as performed, and with their agency located and expressed within and 
as connections among sociotechnical and economic contexts. In the wider project 
we ask three primary questions: 1) what is a digital drug - exploring the conceptual 
and analytical shift from physical/chemical artefacts towards some digital socio-
materiality; 2) how use-practices, markets and business models evolve for semi-
configured and servitized kinds of medicines; 3) consequences for/changes in the 
‘wider whole’ and the relations between the parts/players (pharma and health in-
dustries, payers, research, regulatory practices, patient-doctor relations, etc.). Cut-
ting across these areas are multiple questions of value: therapeutic value, clinical 
value, health enhancement, value as management of risk or reduction of harm, 
market value, value in exchange, value in use, value for money, and ethical values.  
 
Concept  Definitions Digital mechanisms 
Electronic  
prescribing (EP) 
 “The utilisation of electronic systems to facilitate and 
enhance the communication of a prescription or medi-
cine order, aiding the choice, administration and supply 
of a medicine through knowledge and decision support 
and providing a robust audit trail for the entire medi-
cines use process.” (Connecting for Health, quoted in 
[7]) 
On DSS, see also: [8]. For an example of the applica-
tion of DSS and EP in personalized medicine see: [9]   
Decision support; error 
reduction; contributing 
to electronic patient 
record and Big Data 
repositories.  
Stratified  
medicine (SM) 
 
“Refers to the targeting of treatments (including phar-
macological and non-pharmacological interventions) 
according to the biological or risk characteristics shared 
by subgroups of patients.” [10]  
See also:  [11] 
Often combined with, or used as synonym for Personal-
ized medicine (PM)  
“Targeting therapy and 
making the best deci-
sions for groups of 
similar patients”; finding 
those who benefit most 
(or face greater risk), 
finding those who re-
spond to this treatment.  
Personalized medi-
cine (PM); 
“An emerging practice of medicine that uses an indi-
vidual’s genetic profile to guide decisions made in re-
gard to the prevention, diagnosis, and treatment of 
disease. Knowledge of a patient’s genetic profile can 
help doctors select the proper medication or therapy 
and administer it using the proper dose or regime” 
(National Human Genome Research Institute, cited in 
[8]).  
See also: [12] 
Targeting therapy and 
making the best deci-
sions for a specific 
patient, on the basis of  
how the body will re-
spond to treatment; 
selecting the right/best 
therapy on the basis of  
the patient’s ‘omics’ and 
expected response to 
active ingredient(s). 
 
Smart Drug Plat-
forms (SDP) 
“The same pharmaceuticals you take today, with one 
small change: each pill [contains] a tiny sensor that can 
communicate, via a digital health feedback system, vital 
information about medication-taking behaviors and 
body’s response” (paraphrased from[13]). Also seen in 
wearable devices often linked to mobile phone e.g.  
Apple HealthKit.  
 
Smart pills, smart patch-
es (e.g.[14]). Devices and 
platforms for data ac-
quisition and analysis.  
Tight feedback on med-
icines as released in the 
body.    
Medical profil-
ing(MP) 
 
The process of determining a patient’s ‘omics’ (a per-
son’s characteristics in terms of molecular components 
and biological pathways, such as genes, transcriptomic, 
proteomic, metabolomic, and autoantibody) for pur-
poses of PM or SM [15]. See also: [16] 
Informing SM categori-
zations and PM thera-
peutic decisions. 
Value based pricing 
(VBP) 
Payment to drug suppliers on the basis of the therapeu-
tic benefit achieved. [35, 36] 
Linking outcome data at 
patient level to payment; 
rebalance risk/reward 
Pharmacovigi-
lance(PV) 
The assessment of the public health importance of 
potential new signals found in medicines-use data (e.g. 
adverse drug reactions) and the confirmation and quan-
tification of risks identified and risk minimization  
measures (paraphrased from [17]). 
For an example of use of digital sources (e.g. social 
media) for this purpose, see [18] 
Adverse event reporting 
systems, population 
scale outcomes data via 
EHR; prospective analy-
sis.  
Pharmacogenetics 
(PG) 
 “Examines inherited or acquired variations in genes 
that dictate drug response, disposition, or toxicity and 
explores how these variations can be used to optimize 
medication therapy.” [19]  
Similar to PM and MP, but specific to genetic profile 
and pharmaceutical therapy. 
Genomics and genomic 
profiling; epidemiologi-
cal resources. 
Anti-
counterfeiting[AC] 
Falsified medicines are fake medicines that pass them-
selves off as real, authorized medicines. Falsified medi-
cines may: contain ingredients of low quality or in the 
wrong doses; be deliberately and fraudulently misla-
beled with respect to their identity or source; have fake 
packaging, the wrong ingredients, or low levels of the 
active ingredients (paraphrased from European Medi-
cines Agency web site). See also: [20] 
Supply chain integration 
(bar codes, security 
codes; tamper proof 
packaging); consumer 
services (website 
seals/logos) and digital 
services.  
Table 1: A sample of contemporary digital hybrids in medicines use
  
2 Origins and character of digital drugs 
Medicines have always been hybrids (actor networks) - in part biochemical 
actor (active molecule(s)), in part material delivery system (pill, infusion, 
suppository, box, leaflet, cold chain), in part informational resources (rep-
resentations and scripts to validate therapeutics and designate safe and 
appropriate use). And all bound up with complex and diverse social, sci-
entific and economic interests and practices. However, the examples in 
Table 1 suggest that contemporary medicines in use become more materi-
ally, informationally and algorithmically complex, e.g. more digitally po-
tent. We identify these as digital drugs2 - that is: 
‘drugs that are both dependent on and substantially constituted by multiple digital rep-
resentations and connections, and whose use and effectiveness is strongly mediated 
through digital means’  
The lens we use to study digital drugs is assemblage [23] – drugs as per-
formed bundles of artefacts, interests and practices that connect and in-
teract with wider wholes, including clinical work (use), research practices 
that validate utility/value and mitigate/metricate risk (clinical trials, sys-
                                                 
2 There is a possibility that  something like a clinical medicine might emerge and be ad-
ministered in a form that is essential ly a pure digital phenomenon, e.g. an abstract  
‘program’ of biochemical action to be compiled, ‘downloaded’ and ‘run’ in the body. 
More simply, a therapy such as a gym routine might be seen this way.  For example the 
UK NHS ‘Couch to 5K’ is  a therapy embodied in podcast downloads for achieving 
basic fitness  through running [21]. A Google search of ‘digital drugs’ will  also  give in-
formation on possible audio-based psychotropic recreational drugs – so called ‘digital 
highs’. In the sense that  music can change your mood, perhaps even suppress pain, 
this is plausible. However, the general professional opinion is that the technology of 
‘binaural beats’ is an interesting sensory phenomenon but psychotrop ically ineffective 
and that those who do get high are experiencing at best a placebo effect [22].  
tematic reviews, pharmacovigilance) and regulatory frameworks to guide 
practice (regulations, protocols and guidelines).  
In using the concept of assemblage we follow the broadly Deleuzian 
approach [23, 24]. Assemblage signifies digital drugs as events and con-
junctions in time and sources of qualitative difference (something happen-
ing, some things entangled, something noticed, something different, a 
process or processes at work, an enactment). In the Deleuzian vocabulary 
an assemblage is rhizomic, a question of emergence (emergent properties, 
generativity) in open systems – “the always-emergent conditions of the 
present” [23]. An assemblage is not then a ‘thing’ (as in a network), with 
specific life-span or essence. Rather, assemblage is understood in a meta-
physics in which “the concept of multiplicity replaces that of substance, 
event replaces essence and virtuality replaces possibility” [25]. This implies 
actions and performance of complex and multiple causality/functional 
interdependencies (e.g. as a medicine is found in a body or bodies, mod-
eled in a genomic profile, supplied, or prescribed), and is not tied to a 
fixed format or a single unambiguous event or outcome. This is in con-
trast to the term hybrid used here to refer to the (digital) drug as artefact 
and actor, including its mix of material/digital resources and its evolved 
sociomaterial agency. We might say that  assemblage is a concept applied to 
the ‘instantiation’ of the drug hybrid in use – the ‘here and now’ in a con-
text (including in virtual contexts and in simulations).  
We approach digital drugs by opposing the concept to its non-digital or 
pre-digital i.e. analogue version. The generations of medicines within our 
established regulatory structures, including the post-Thalidomide medi-
cines, are essentially analogue drugs –seen as organic artefacts operating in 
an organic world of the body. Norbert Wiener, commenting on the prob-
abilistic world of quantum mechanics, notes “the recognition of a funda-
mental element of chance in the texture of the universe” [26][p11]. In this 
sense anything analogue/organic is incomplete and uncertain (“...this ran-
dom element, this organic incompleteness” [p11]). This ‘incompleteness’ 
certainly applies to medicines and their use. We are used to (or resigned 
to) the ‘quantum’ effect in medicines even as we strive for a stronger and 
stronger evidence base and thus certainty. Indeed the quantum is rather 
large given that most drugs prescribed to people do not work as desired 
most of the time3. Contemporary moves to digitize medicines may be seen 
as an attempt at closing down ‘this organic incompleteness’ within a digi-
tal certainty - e.g. through stratified medicine, genomics etc. as well as an-
ti-counterfeiting systems or pharmacovigilance. It is tempting to imagine, 
as some proponents of these approaches do, that the shift to digital will 
drive down the quantum effect as it opens access to mechanisms that can 
validate actions and reduce error terms by orders of magnitude. This is 
not our position. Through the concept of assemblage, we argue, the quan-
tum of the digital is made apparent, seen for example, in the simulated or 
more generally in the multiplicities that digital ontology accommodates.   
 Yoo’s definition of digitalization recognizes this transition from analog 
to digital as fundamental: ‘the encoding of analog information into a digital format 
                                                 
3 The average NNT (Number Needed to Treat) for a licensed drug used in secondary 
care is well over 5, and for a prophylactic drug (e.g. aspirin for prevention of stroke) it  
may be well over 1000; that  is over 1000 persons need to receive the drug, including 
paying for it  and suffering possible side effects, for one to obtain a therapeutic benefit  
[27]. As a point of contrast everyday paracetamol (acetaminophen) which a dentist 
may give you after an  extraction has an  NNT of around 4.5 for post-operative pain  
[28].  
and the possible subsequent reconfigurations of the socio-technical context of production 
and consumption of [the associated] products and services’  [29][p.137]. He proposes 
that such digitalization occurs in various ways: at the level of a physical 
object (e.g. a digital infusion pump in place of an analog gravity infusion 
roller clamp; a 3D tamper proof bar code on a package), at the level of 
digital/digitally mediated routines (a digital algorithm for prescribing; a 
smart phone app to raise adherence to therapy), or as new representations 
(a genomic account of personalized efficacy; a digital information resource 
on drug-drug interactions driven by massive electronic health records da-
tabases).  
Any division between a digital drug (and digital quantum) and an ana-
logue drug (and organic quantum) is not of course clear cut. Transitions 
occur over years as existing resources are reconfigured in digital forms and 
new resources added or retro-fitted. Our argument is, however, that as 
more of the active work we expect medicines to do (their agency) is 
(co)located in the digital, as digital resources and mechanisms are added 
and combined, and as this agency (re-)aligns to specific interests and goals, 
be they therapeutic, social or economic, then the nature of what a drug is, 
and how a medicine of medicines is practiced, ‘tips’ and something dis-
tinct and new emerges – a different kind of drug, a different set of prac-
tices, different assemblages. This in turn implies, we argue, new social, 
organizational and market structures.  
Thus, as Yoo’s definition of digitalization suggests and as assemblage 
requires, our interest is not focused ultimately on the digitizing of the in-
formation/object or the new digital routines or new representations, sig-
nificant though these are - and of course we do need to consider the spe-
cific characteristics of digital products and services (as products/artefacts 
and as representations/services) and the ‘bit string’ economics that they 
obey [30]. But it is the ‘subsequent reconfigurations’ that are foreshad-
owed as seen in events and actions that we explore.  
3 Three domains: (in-)use, research, governance 
We approach digital drugs as assemblage from the perspective of three 
traditional domains in which they are by convention ‘assembled’ and with-
in which issues of their value are addressed. These are the domain of clin-
ical and therapeutic use, the domain of reflexive enquiry and research 
(gathering of ‘evidence’, knowing), and the domain of regulation and gov-
ernance. These three domains are well established, each with its own prac-
tices and an established role/narrative as how we benefit (or not) from 
medicines. We do not consider here the biochemical domain, important 
though it is. These domains are of course interlinked, and one of the char-
acteristics of medicines digitization is that these domains connect more 
and more e.g. events/assemblages are larger, stronger, richer, and more 
dynamic.  
3.1 In-Use 
As suggested above, digital drugs emerge in part out of efforts to comput-
erize existing medicines use practices (prescribing, supply, administration, 
adherence, etc.) and in this way ‘digitalize the object’ with consequential 
ontological changes. Since the turn of the millennium it has been a key 
ambition of developed country health care policies to computerize pre-
scribing in both primary care and secondary care and specifically to ex-
ploit the benefits of clinical decision support systems (CDSS) in helping 
prescribers select the right medicine for the patient, and to do so on the 
basis of a (digital) medical record (e.g. providing clinical data including in 
areas such as allergies), and data on recommended therapeutic strategies, 
available medicines, cost/cost effectiveness, and the effects of interaction 
among them (e.g. [31]). Similarly in the administration of medicines to or 
by patients, technological systems and devices such as smart pill boxes or 
text alerts are deployed to encourage or enforce adherence and record 
actual use [32]. Much of this work has necessarily been piecemeal (perhaps 
better described as ‘targeted’) as specific clinical practices and operational 
needs have been given computer ‘support’ (prescribing, dispensing, sup-
ply, administration, audit, ‘academic detailing’, phamacovigilance , etc.). 
CDSS are also understood as a necessary technological infrastructure, a 
necessary representation, without which a widespread application of per-
sonalized medicine cannot be contemplated [33], e.g. to enable the use in 
clinical practice of the 2500 genetic tests now already available [8] [34].  
The potential therapeutic value and/or service value that motivate such pro-
jects include improved safety and reduction in errors and harm, more 
consistency of (good) practice, more efficient operations with less waste, 
and better documented therapy. In this way initiatives to computerize 
medicines-use are by convention set against the familiar litany of contem-
porary existential health care problems: rising health care costs, unac-
ceptable error rates and the harm they cause, demographic change, man-
aging a growing burden of treatable chronic disease. Ambitions of pro-
gress in these areas are predicated on the existence of good informational 
infrastructures that represent valid forms of data (e.g. [35]). Many of these 
ambitions have not yet been fully met but the quality, coverage and scale 
of data infrastructures improves over time.  
More system-focused policy motives reflect a desire for more net value 
(i.e. more health benefit and less harm) and value for money out of budgets 
for medicines. In the English NHS about 50 million population generate a 
yearly drugs bill of about £12bn. This leads to a perceived need to exploit 
digital technologies both to help control this significant line of expendi-
ture and to increase the effectiveness of what is spent in improving health 
outcomes.  
Models of the use of digital drugs and their regulation are founded on 
ideas of digital systems for establishing efficacy, expressing protocols and 
in the realization of individual patient’s care pathways. This approach to 
medicines and their use is portrayed as offering a ‘personalized’ (or strati-
fied) service (or services) wrapped around the medicine. Perhaps most 
significantly, the personalization process – the process to match your ge-
netics and medical history, test results and other ‘omics’ 4   to what is 
known about medicines and therapy - becomes a separate institutional 
endeavor. Thus a new industry of ‘diagnostics’ has emerged (with economic 
value) which serves through devices, tests, data analysis and protocols to 
control and target therapy choice and therapy delivery – generating a tra-
jectory of events. This is an arena of practice in which the balance of 
business interests and clinical or public health interests is today unclear. 
                                                 
4 Omics: a neologism used to describe a range of scientific fields (proteomics, genomics 
etc.) studying important biomedical aspects about a patient or patient group for su b-
sequent use in personalised  or stratified medicine; used also to refer to a person’s 
characteristics  in  terms of molecular components and biological pathways  (e.g.  tran-
scriptomic, proteomic, metabolom-ic). 
More generally the development of an industry and services for diagnos-
tics can be seen as an example of a ‘service-dominant logic’ (servitisation) 
[36] as a drug becomes less a standard product, and is more performed by 
a complex set of value generating services (value here being taken in multiple 
senses of the word; see above). The clinical utility of the therapeutic inter-
vention (its relevance and usefulness in patient care [37]) “becomes a 
moving target” as information on its benefits and risks increases for 
groups or for individual patients [37]. As part of this, ’patients’, their bod-
ies and their carers may (but it is in no way inevitable) become more active 
participants in therapy, with their involvement too digitally mediated – a 
possible reconfiguration of the patient and their role as actor and infor-
mation source (e.g. in consultations) to a data source (e.g. through wireless 
monitors or smart pills).  
The health value a medicine generates, and the ability to identify this, 
becomes an open and multiple question – how to find a value-in-use (e.g. 
the model of a market in services, and in particular digital services). This 
moves away from traditional ideas of a value-in-exchange (the model of a 
market for products). This change in perspective is directly seen in con-
temporary policy debates as national systems and payers consider ‘value 
based pricing’– e.g. paying (or not paying) for the therapeutic service (or 
outcome), not for the molecule, and using a multi criteria algorithm and 
feedback to identify those that pass the value test and those that fail it [38, 
39]. 
3.2 Research – evidence in the doing 
A large armory of methods and techniques are today available to support 
scientific enquiry into medicines biochemical efficacy and other conse-
quences and side effects (e.g. their validation as safe and effective) includ-
ing statistical measures of outcomes as in a controlled trial, and synthetic 
metrics such as Number Needed to Treat (NNT) and Number Needed to 
Harm (NNH). These methods, refined in the past 70 or so years, under-
pin the established processes through which a new medicine is developed, 
tested and then licensed for specific uses. It is also the basis for the prima-
ry means by which a healthcare professional is given guidance on what 
medicines to use, when and how. Research findings are synthesized into 
protocols or guidelines for practitioners based on clinical data with or 
without some element of health economics (value for money).  
In the UK for example, a national body - the National Institute for Health 
and Care Excellence (NICE) - prepares guidance on drug treatments which 
balances clinical and therapeutic benefits against cost5.  Fundamental to 
this is the use of randomized control trials (RCT) and the types of 
knowledge that can be derived from trials, both individually and through 
meta-analysis (e.g. Cochrane reviews). It is in this way that we confidently 
(i.e. within confidence intervals, given the ‘random element and organic 
incompleteness’ of life) assert the therapeutic value and risks of a new 
medicine for specific conditions and/or subpopulations, or recompute 
them for older drugs. However clinical trials in their traditional form are 
                                                 
5  
http://www.nice.org.uk/guidance/index.jsp?action=bytreatment&TREATMENTS=Dr
ug+treatments  Last accessed 15 September 2014 
increasingly considered unsuitable to obtain the evidence on benefits and 
risks of medicines tailored to specific individuals – for example a trial now 
has to assess both the efficacy of the treatment and the efficacy of the 
diagnostic that underpins the stratification, the co-dependent develop-
ment of drugs and molecular diagnostics [40]. As Lewis et al (2014) sug-
gest of personalized medicine “[It] forces us to question contemporary 
biomedical views of evidence, including its generation and use in decision 
making” [40]. There is thus a new focus on a set of complementary ap-
proaches to metricate value generated by medicines as they are to be used 
and as they are revealed through intensive digitization in the domain of 
use. Individual patient data collected/entered by clinicians at the point of 
care, or provided by the patient (now a data source), are aggregated into 
‘Big Data’ as a potential basis for a new knowledge. A range of new ana-
lytic tools analyze or ‘mine’ these often non-standardized data and sift 
through the ‘data turmoil’ [41].  Among these analytic resources, for ex-
ample, are new data-driven approaches to test the relationship between 
biomarkers and clinical outcomes [42] or for standardizing function in-
stead of components in RCTs of complex interventions [43]. Alternative-
ly, “real-time surveillance of individual patient outcomes” [37] may com-
plement trials and improve evidence and support personalization. Draw-
ing on digital resources, trials and experiments can be set up as “random-
ized studies embedded in routine care” through the use of electronic pa-
tient record databases [41]. Through such means  the duration of trials 
and evidence gathering will shorten, some hope. For example, with an 
active distributed surveillance system in place “a full-scale observational 
study to evaluate the association between angioedema and drugs targeting 
the renin–angiotensin system was designed, conducted, and completed in 
11 months” [44]. The perception of the need for such methods and the 
sense of urgency to exploit new research opportunities can be traced in 
part to the case of the pain killer and anti-inflammatory drug Vioxx. This 
medicine was licensed in 1999 and withdrawn in 2004. It took over 3 years 
and a number of patient deaths (disputed but probably in 6 digits [45]) 
before the negative side effects were acknowledged by the makers and the 
drug withdrawn from the US market [46]. The proposition is that, with 
digitalized patient records, and an effective and proactive pharma-
covigliance system, such a case could be identified earlier with overall less 
harm. [44]  
3.3 Governance and Regulation  
Research designs reflecting digitization, as described above, imply signifi-
cant modifications to regulatory regimes. Regulators have been among the 
most active in adapting to the new world of digital drugs. The FDA, the 
US regulator, has made many changes in its processes to accommodate a 
perceived new urgency in drug approval processes including a fast-track 
process for ‘breakthrough therapies’ [47]. There is a somewhat similar 
designation of ‘orphan drugs’ in medical areas where patient numbers are 
small and investments are unlikely to be made on the usual commercial 
basis. If and when medicines are fast tracked (a concept with a history 
traced back to the early period of HIV/AIDS), and are expected to have a 
weaker research provenance at the time of licensing, they rely more on 
digital resources for monitoring of “post marketing safety and effective-
ness” [44]. In such circumstances medicines-in-use data can serve to “raise 
or lower the level of concern about the overall risk–benefit profile of par-
ticular drugs”, a capability that is described by the FDA as being trans-
formational for the licensing process [44]. More generally they 
acknowledge the ability of these new resources of data to help fulfil the 
FDA’s role. In the own words of the FDA, it has “evolved its regulatory 
processes in response to – and in anticipation of – scientific develop-
ments” [48], noting how it has responded to personalized medicines and 
the associated growth of diagnostic products by, “collaborating in key 
research, defining and streamlining regulatory pathways and policies, and 
applying new knowledge in product reviews” [48].  Meanwhile, Australia 
has, arguably, the first national framework to assess personalized medicine 
for coverage or reimbursement decisions [49]. 
As suggested above, digitization and the availability of data generated in 
clinical care practices (in-use) and held in national registries, migrate from 
a pure research (trial) status to embody more directly various interests 
including of health care system managers and the payers, patients and pa-
tient groups, and the pharmaceutical industry [50, 51]. That is, research in 
both new and old formats, and digitalized and synthesized prospective 
data sets become engaged in the systems of governance and regulation 
that surround medicines use. Research data thus will directly feed the de-
velopment of detailed and comprehensive protocols of use (and non-use) 
for powerful and expensive drugs, described as frameworks for ‘appropri-
ate medicines use’ [50]. Niezen et al. report research in The Netherlands 
on registries (national databases of medicines use for a specific class of 
patient) as digital artifacts that are both an object to be managed, and an 
instrument to manage with. In this way clinical work (using medicines 
with patients and feeding the registry) and regulatory work (setting the 
protocol guidelines and reimbursement rules) become closely co-
constitutive and co-evolving. In their analysis they question the desirability 
of a regulatory system that pursues a new ‘digital objectivity’ where availa-
ble data embodies truth – as seen in many Big Data endorsements, and 
captured in the idea of the ‘death of the denominator’ when  n=All (see 
also [52]). They contrast such digital objectivity with the more established 
‘regulatory objectivity’, the kind of knowledge that is based on mu ltiple 
evidential resources and embodies conventions and trade offs and collec-
tive expertise [53, 54].  
3.4 Conclusion 
In this paper we introduce the new concept of digital drugs as the intensi-
fied integration of digital services, data resources and algorithms into the 
practices of medicines. We anatomize it to reveal some of the main com-
ponents (use, regulation, research) and mechanisms and relations using 
the lens of assemblage. The digitalization efforts that characterize the 
movement towards digital drugs are for the most part undertaken in the 
name of understanding, best practice, precision, and certainty. The indi-
vidual initiatives and innovations described here can be seen individually 
as the expression of some regular and rational plan or policy to enhance 
the efficacy and efficiency of health care. Our view, our conceptual reper-
toire, and our chosen lens of assemblage, however, suggest something else 
or at least a different account of motivations and mechanism. As pro-
posed here, digitization (digital mediation of drugs) is pursued as a means 
to address the organic quantum of chemicals in the body. However, the 
complexity and multiplicity of elements that converge in or constitute a 
digital drug and its ‘use/reuse’ suggest that it need not, and perhaps 
should not, be seen as a pursuit of a certain or specific outcomes. Digital 
drugs are manifest as diverse, distributed, cumulated and dissected events 
and incidents across and between domains. They also permit multiple 
outcomes as data resources grow, algorithms learn and reconfigure, and 
virtual phenomena take new roles. Such multiplicity and instability is a 
price paid for the desired outcomes, for example in the case of in-use ex-
perimental designs or big data driven protocols (digital objectivity).  
Markus and Saka introduce assemblage as a technique of collage and 
“something that generates enduring puzzles about ‘process’ and ‘relation-
ship’” and “[offers] an odd, irregular and time-limited object for contem-
plation” [23]. Applying it in these terms to medicines, this paper raises 
issues that might be assessed against a wider understanding of digitaliza-
tion.   
First, is the idea of digital drugs themselves, or more generally of 
movement (re-configurations) towards a digital materiality that attaches to 
and ‘takes over’ classes of artifacts. In this it recasts them ontologically 
away from an artefactual existence to one of assemblage - found in a 
complex ecosystem of data, algorithm and temporally unstable conjunc-
tions, actual, real, virtual or simulated. 
Second, and embedded within this perspective, is the question of the 
’mechanisms’ of the digital as rational processes of improvement, as (digi-
tal) controllers, as sensemaking, and as generative forces. Our case, and 
the examples in Table 1, suggests that there is opportunity here for useful 
fundamental categorizations of this digital agency through artefactual and 
assemblage conceptualizations. 
Third and finally, is the question of knowledge processes (research de-
signs) as embedded in these phenomena. The methodological arsenal of 
the evidence based community (that of innovators, regulators and evi-
dence-based practice) is changing and adapting. Event and transaction are 
at the core, able to be inspected, accumulated and animated in ways that 
were not possible in earlier eras. This reconfiguration is core to the phe-
nomena of interest.  But can the IS community reconfigure its research 
agendas and methods to meet this challenge?  
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